Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

LGD-4033 and Masteron Interaction: Synergistic | Peptide Database

Compound Profiles LGD-4033 Selective Androgen Receptor Modulator | Lean Mass LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its t

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Masteron

DHT-Derived Anabolic Steroid | Hardening & Anti-Estrogenic

Drostanolone binds to the androgen receptor with high affinity, promoting protein synthesis and nitrogen retention in skeletal muscle. As a DHT derivative, it cannot be converted to estrogen by the aromatase enzyme, eliminating estrogen-related side effects such as water retention and gynecomastia from the compound itself.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take LGD-4033 with Masteron?

Yes, LGD-4033 and Masteron can generally be taken together. Masteron helps manage estrogen conversion from LGD-4033. This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen.

Is LGD-4033 and Masteron safe together?

Based on pharmacological analysis, this combination is considered synergistic. However, shared safety flags include: androgenic, blood pressure raising, carcinogenic risk, hpta suppressive, lipid disrupting, teratogenic. Monitor accordingly.

What are the interactions between LGD-4033 and Masteron?

Masteron helps manage estrogen conversion from LGD-4033. This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen. This assessment has 60% confidence and is inferred from pharmacological mechanism analysis.

How should I time LGD-4033 and Masteron?

LGD-4033 has a half-life of ~24-36 hours and Masteron has a half-life of ~2 days (propionate), ~10 days (enanthate). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

Reduces body fat by increasing energy expenditure and fat oxidation without reducing food intake. Research shows reversal of diet-induced insulin resistance in mouse models. Addresses multiple components of metabolic syndrome through enhanced energy expenditure. 2024 research shows combining BAM-15 with semaglutide produces stronger metabolic benefits than either alone by countering metabolic adaptation. May help overcome weight loss plateaus by preventing metabolic adaptation/efficiency. Research shows decreased liver triglycerides in treated animals. Improved glucose tolerance observed in research models.

Source: peptide-db.com ↗

Research Indications

By increasing dopamine synthesis capacity, bromantane enhances baseline motivation, initiative, and the ability to engage in and sustain effortful tasks. Users consistently report improved ability to start and complete demanding cognitive work. Provides a clean, non-jittery mental energy that supports prolonged cognitive effort. Unlike stimulants that front-load neurotransmitter release and lead to a crash, bromantane's gene-expression-level mechanism delivers steady-state enhancement over the course of the day. The combination of dopaminergic upregulation and anxiolytic activity makes bromantane particularly useful for maintaining cognitive performance during periods of high psychological or physical stress. Approved in Russia for the treatment of asthenic disorders with anxiety. Clinical trials demonstrated significant reductions in anxiety scores without the sedation, cognitive dulling, or dependence potential of benzodiazepines. Primary approved indication in Russia. Bromantane addresses the fatigue, reduced drive, and emotional instability characteristic of asthenic conditions, restoring normal energy and emotional regulation. As an actoprotector, bromantane improves physical endurance and recovery under conditions of heat stress, sleep deprivation, and sustained exertion. Originally developed for military applications requiring sustained physical output in adverse environments. Some evidence suggests improved recovery from physical exertion, likely related to both the dopaminergic enhancement of central drive and the anxiolytic reduction of stress-mediated cortisol elevation.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Propranolol is administered orally as an immediate-release tablet or extended-release capsule. The immediate-release formulation reaches peak plasma concentration within 1-2 hours, with clinical effects (heart rate reduction) noticeable within 30-60 minutes. Bioavailability is approximately 25-35% due to extensive first-pass hepatic metabolism via CYP2D6 and CYP1A2. Food increases bioavailability by reducing first-pass extraction. The drug is highly lipophilic with a large volume of distribution (approximately 4 L/kg), readily crossing the blood-brain barrier. Elimination half-life is 4-5 hours for the immediate-release formulation. As-Needed Anxiety Management 10-40 mg 30-60 minutes before event Oral Tren/AAS Cycle Heart Rate Control 20-80 mg/day Divided into 2-3 doses daily Clenbuterol Heart Rate Mitigation 10-20 mg 1-2 times daily (as needed with clen doses)

Source: peptide-db.com ↗
Side effects

Common Side Effects

Gastrointestinal discomfort (diarrhea, abdominal pain) - mild and infrequent, reported at similar rates to placebo Upper respiratory tract infection (reported in clinical trials but not clearly drug-related) Fatigue and headache (uncommon, typically transient)

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides